{
    "clinical_study": {
        "@rank": "112593", 
        "arm_group": {
            "arm_group_label": "HIGH DOSE CHEMOTHERAPY AND ASCT", 
            "arm_group_type": "Experimental", 
            "description": "This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety of delivering the patients' own immune\n      cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell\n      transplantation (ASCT)."
        }, 
        "brief_title": "High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Transplant eligible patients will be eligible if criteria met per below.\n\n        Inclusion Criteria:\n\n          -  Patients > or = to 18 years of age with aggressive B-cell non-Hodgkin lymphoma\n             subtypes including, but not limited to, relapsed or refractory diffused large B-cell\n             lymphoma (DLBCL), Burkitt's lymphoma or transformed indolent B-cell non-Hodgkin\n             lymphoma (including chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia\n             (SLL) meeting at least one of the following criteria:\n\n               -  Bone marrow involvement at the time of relapse or refractory disease and not\n                  appropriate for allogeneic transplantation.\n\n               -  PET positive disease outside of one radiation port unless single-port disease\n                  treated with prior radiotherapy within the port, following > or = to 2 cycles of\n                  salvage chemotherapy, 1999 IWG criteria (section 12.2 and 12.383).\n\n          -  Creatinine < or = 1.5 mg/100 ml (or measured 24 hour creatinine clearance of > or =\n             to 50 cc/min)\n\n          -  Bilirubin <2.0 mg/100 ml, AST and ALT <3x the upper-limit of normal, PT and PTT < 2x\n             normal outside the setting of stable chronic anticoagulation therapy,\n\n          -  Granulocytes >1,000/mm3, platelets >50,000/mm3, hemoglobin >8.0g/dl.\n\n          -  Adequate cardiac function (LVEF>40%) as assessed by ECHO or MUGA scan performed\n             within 1 month of treatment.\n\n          -  Adequate pulmonary function as assessed by DLCO of > or = to 45% adjusted for\n             hemoglobin.\n\n          -  Life expectancy of > 3 months.\n\n        Exclusion Criteria:\n\n          -  Karnofsky performance status < or = to 70 (see appendix VI).\n\n          -  Patients previously treated with allogeneic bone marrow or stem cell transplantation\n             are ineligible.\n\n          -  Other past or current malignancy unless in the opinion of the investigator it does\n             not contraindicate participation in the study.\n\n          -  Uncontrolled bacterial, viral or fungal infection.\n\n          -  Patients with HIV, active hepatitis B or hepatitis C infection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840566", 
            "org_study_id": "12-117"
        }, 
        "intervention": [
            {
                "arm_group_label": "HIGH DOSE CHEMOTHERAPY AND ASCT", 
                "intervention_name": "Carmustine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HIGH DOSE CHEMOTHERAPY AND ASCT", 
                "intervention_name": "Etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HIGH DOSE CHEMOTHERAPY AND ASCT", 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HIGH DOSE CHEMOTHERAPY AND ASCT", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HIGH DOSE CHEMOTHERAPY AND ASCT", 
                "intervention_name": "Pegfilgrastim", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "HIGH DOSE CHEMOTHERAPY AND ASCT", 
                "intervention_name": "19-28z T CELLS", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "HIGH DOSE CHEMOTHERAPY AND ASCT", 
                "intervention_name": "Autologous Stem Cell Transplantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carmustine", 
                "Melphalan", 
                "Cytarabine", 
                "Etoposide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Relapsed", 
            "Refractory", 
            "Autologous Stem Cell Transplantation", 
            "HIGH DOSE CHEMOTHERAPY", 
            "19-28z T cells/kg", 
            "12-117"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Craig Sauter, MD", 
                "phone": "212-639-3460"
            }, 
            "contact_backup": {
                "last_name": "Jenna Goldberg, MD", 
                "phone": "212-639-4828"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Craig Sauter, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma", 
        "overall_contact": {
            "last_name": "Craig Sauter, MD", 
            "phone": "212-639-3460"
        }, 
        "overall_contact_backup": {
            "last_name": "Jenna Goldberg, MD", 
            "phone": "212-639-4828"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Craig Sauter, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "will be assessed utilizing a standard 3+3 cell dose escalation to determine the maximum tolerated dose of CD19+ CAR T cells", 
                "measure": "maximum tolerated dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Toxicity will be graded on a scale of 1 to 5 as described by the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0", 
                "measure": "safety", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840566"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "2 year progression-free (PFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "overall survival (os)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}